DexCom, Inc. DXCM
Strong Medical Devices & Diagnostics sector · Continuous glucose monitors — recurring sensor revenue as diabetes care goes wearable.
DexCom, Inc. (DXCM) is an established Medical Devices & Diagnostics company, graded Strong on FrontierLab's evidence-based quality rubric (data as of 2026-08-21). Revenue grew 15.5% year-over-year at a 62.5% gross margin. Gross-profits-to-assets is 0.48; Rule of 40 is 38.4. Net share issuance -4% YoY (buying back shares). 1 risk flag is noted below. Analyst mix: 31 buy / 5 hold / 0 sell.
These sentences are generated from the day's data by deterministic templates.
Key quality signals
| Revenue growth (YoY) | 15.5% |
|---|---|
| Gross margin | 62.5% |
| Gross profits / assets | 0.48 |
| Rule of 40 | 38.4 |
| Net margin | 22.9% |
| Cash runway (months) | — |
| PEG | 0.5 |
| Price / sales | 6.9 |
Quality checklist
Each line is one quality test behind the grade — ✓ passed · ~ borderline · ✗ failed. Hover a metric in the tables below for what it means.
- ~ Revenue growth — 15.5% (pass ≥ 20%)
- ✓ Gross profits / assets — 0.48 (pass ≥ 0.33)
- · Rule of 40 — 38.4 (context — graded for software only)
- ✓ Gross margin — 62.5% (pass ≥ 60% · Medical Devices & Diagnostics)
- ✓ Cash generation
- ✓ Share dilution — -4%
- ~ Competitive moat — Narrow
- ✓ Market size (TAM) — Large
Grade history
Graded Strong since 2026-06-10 — no grade changes recorded yet.
How have Strong-graded names performed?
The forward returns of all Strong-graded names since each grade was recorded — the bucket this name currently sits in, not a forecast of this individual stock.
| Window | Forward record vs the S&P | Median |
|---|---|---|
| ~1 month | 59% of Strong-graded names beat the S&P over 21 sessions (95% CI 41–74%, N=29). | Median excess vs the S&P was +4.2%. |
| ~3 months | building — 13 more sessions needed | |
| ~6 months | building — 76 more sessions needed | |
How have this name's flags scored?
| Flag | N | Mean excess vs S&P |
|---|---|---|
| Parabolic one-day spike (+12%) in the last month — extreme single-day moves tend to mean-revert. | sample still too small to report (need ≥ 8) | |
These per-flag figures are observational — a flag firing is not a randomized assignment, so any edge can reflect what kind of names trip a flag, not the flag itself. Descriptive, not causal.
Scope: these are forward returns vs the S&P among names still covered at each horizon's end, within the curated universe — not a survivorship-clean whole-market backtest. Names later dropped from coverage are counted as attrition (not hidden), and single-session moves beyond ±300% are treated as split/data artifacts and excluded. How this is measured → · Full track record →
How it compares
Coarse same-sector, same-stage context — not a percentile or rank. GP/A is graded on its absolute level, not position.
Fundamentals
| Market cap | $34.05B |
|---|---|
| Stage | Established |
| Share issuance (YoY) | -4% · buying back shares |
| Moat | Narrow |
| TAM | LARGE |
| P/E (trailing) | 35.7 |
| EPS (trailing) | $2.53 |
| Burn multiple | — |
| Gross-margin trend (pts) | 3.7 |
| Cash / assets | 0.3 |
| Accruals (%) | -10.9% |
| Net debt / EBITDA | 0.2 |
| Statements as of | Q2 FY2026 · filed 2026-07-30 |
Momentum context — describes the past, not a signal
Low reached Nov 10, 2025 · high reached Aug 13, 2026 — by daily close.
| Price | $90.22 (as of 2026-08-20) |
|---|---|
| Last session move | — |
| % off 52-wk high | -1.9% |
| RSI (14) | 67 |
| Relative volume | 0.9× |
Risk flags
Insider activity (90 days)
| Cluster buyers | 0 |
|---|---|
| Sellers | 5 |
Insider selling is routine diversification, not a bearish signal.
Analyst mix
| Strong buy | 15 |
|---|---|
| Buy | 16 |
| Hold | 5 |
| Sell | 0 |
| Strong sell | 0 |
▼ Analyst view softening — net -2 buy ratings, coverage 38→36 analysts over ~4 weeks (per aggregated analyst ratings)
Ratings are context, not a price target. "Momentum" = how the mix changed over recent weeks, not a forecast.
From the headlines
Strong growth and bullish technicals offset valuation concerns.
- Dexcom (NASDAQ:DXCM) Combines Strong Growth With a Bullish Technical Setup
- DexCom (DXCM) Rebounds On Growth Hopes, Does It Look Fully Valued?
- DexCom (DXCM) Stock Sees Modest Fair Value Lift After Q2 And Clinical Updates
AI take — daily, AI-generated
AI leans positive
Rare combo of strong growth (15.5%), excellent PEG (0.5), and shrinking dilution—valuation concerns are overblown relative to the fundamentals.
Generated by an AI model from the day's news — an opinion for context only. Not financial advice, not a recommendation, and not a price target.
Similar Medical Devices & Diagnostics names
← All Medical Devices & Diagnostics names · Open DXCM in the interactive screener →
Data as of 2026-08-21 08:12 (end-of-day). How grades are computed →